Chinese fine chemicals manufacturer Huadao Biopharma announced last week the completion of a series B round of financing worth RMB100 million (US$14.18 million) led by Shenzhen-listed chemicals developer NKY Medical Holdings. Ren Dalong, the vice president of NKY Medical Holdings, also participated in the new round, said Huadao in a statement released on its WeChat […]

Chinese Fine Chemicals Manufacturer Huadao Biopharma Closes $14M Series B Round comes originally from China Money Network. All Rights Reserved.